Q32 Bio is a clinical-stage biotechnology company dedicated to discovering and developing biological therapeutics that restore healthy immune balance to treat severe autoimmune and inflammatory diseases. Its primary clinical pipeline programs focus on conditions driven by profound immune dysfunction, most notably alopecia areata, where T cell-mediated pathways damage hair follicles. Additionally, the company's scientific platforms address other inflammatory and dermatological conditions, such as atopic dermatitis, by targeting fundamental drivers like interleukin pathways and tissue-specific complement system deposition.